Search This Blog

Monday, November 27, 2023

Xenon depression drug fails to meet main goal in study

 Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study.

https://finance.yahoo.com/news/1-canadas-xenon-pharmas-depression-123034333.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.